Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 97
Filter
1.
Antimicrob Agents Chemother ; 60(8): 4734-42, 2016 08.
Article in English | MEDLINE | ID: mdl-27216076

ABSTRACT

A simple and rapid ultra-high-performance liquid chromatography (UHPLC) method using UV detection was developed for the simultaneous determination of eight ß-lactam antibiotics in human plasma, including four penicillins, amoxicillin (AMX), cloxacillin (CLX), oxacillin (OXA), and piperacillin (PIP), and four cephalosporins, cefazolin (CFZ), cefepime (FEP), cefotaxime (CTX), and ceftazidime (CAZ). One hundred-microliter samples were spiked with thiopental as an internal standard, and proteins were precipitated by acetonitrile containing 0.1% formic acid. Separation was achieved on a pentafluorophenyl (PFP) column with a mobile phase composed of phosphoric acid (10 mM) and acetonitrile in gradient elution mode at a flow rate of 500 µl/min. Detection was performed at 230 nm for AMX, CLX, OXA, and PIP and 260 nm for CFZ, FEP, CTX, and CAZ. The total analysis time did not exceed 13 min. The method was found to be linear at concentrations ranging from 2 to 100 mg/liter for each compound, and all validation parameters fulfilled international requirements. Between- and within-run accuracy errors ranged from -5.2% to 11.4%, and precision was lower than 14.2%. This simple method requires small-volume samples and can easily be implemented in most clinical laboratories to promote the therapeutic drug monitoring of ß-lactam antibiotics. The simultaneous determination of several antibiotics considerably reduces the time to results for clinicians, which may improve treatment efficiency, especially in critically ill patients.


Subject(s)
Anti-Bacterial Agents/blood , beta-Lactams/blood , Amoxicillin/blood , Cefazolin/blood , Cefepime , Cefotaxime/blood , Ceftazidime/blood , Cephalosporins/blood , Chromatography, High Pressure Liquid/methods , Cloxacillin/blood , Drug Monitoring/methods , Humans , Oxacillin/blood , Piperacillin/blood , Ultraviolet Rays
2.
Eur J Clin Pharmacol ; 70(8): 957-63, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24858821

ABSTRACT

BACKGROUND: Patients suffering from critical limb ischemia (CLI) have poor wound healing in the ankle and foot areas. Secondary wound infections are frequent and often treated with prolonged courses of antibiotics. PURPOSE: This study set out to investigate to what extent the unbound fraction of 4 g of cloxacillin i.v. reaches its target organ in poorly vascularized tissues, i.e., the calf and foot of patients suffering from CLI. METHODS: Cloxacillin concentrations were measured by HPLC in serum and in microdialysis samples from skin and muscle of the lower part of the calf and as reference subcutaneously at the pectoral level in eight patients suffering from CLI (four males, four females, mean age 78 years, range 66-85 years) and in three healthy controls (two females, one male, mean age 67, range 66-68 years). RESULTS: In patients suffering from CLI, the tissue penetration of cloxacillin after a single 4 g dose was comparable to that of healthy controls, despite impaired blood circulation. CONCLUSIONS: The reduced blood flow in the peripheral vessels of the CLI patients presented here apparently is not the rate-limiting factor for delivery or tissue penetration of cloxacillin.


Subject(s)
Anti-Bacterial Agents/pharmacokinetics , Cloxacillin/pharmacokinetics , Ischemia/metabolism , Aged , Aged, 80 and over , Anti-Bacterial Agents/blood , Chronic Disease , Cloxacillin/blood , Female , Humans , Ischemia/therapy , Leg/blood supply , Male , Muscle, Skeletal/metabolism , Subcutaneous Fat/metabolism
3.
Mol Pharm ; 9(8): 2358-63, 2012 Aug 06.
Article in English | MEDLINE | ID: mdl-22784220

ABSTRACT

The aims of this work were to study pharmacokinetics of randomly selected drugs in plasma and saliva samples in healthy human volunteers, and to introduce a Salivary Excretion Classification System. Saliva and plasma samples were collected for 3-5 half-life values of sitagliptin, cinacalcet, metformin, montelukast, tolterodine, hydrochlorothiazide (HCT), lornoxicam, azithromycin, diacerhein, rosuvastatin, cloxacillin, losartan and tamsulosin after oral dosing. Saliva and plasma pharmacokinetic parameters were calculated by noncompartmental analysis using the Kinetica program. Effective intestinal permeability (Peff) values were estimated by the Nelder-Mead algorithm of the Parameter Estimation module using the SimCYP program. Peff values were optimized to predict the actual average plasma profile of each drug. All other physicochemical factors were kept constant during the minimization processes. Sitagliptin, cinacalcet, metformin, tolterodine, HCT, azithromycin, rosuvastatin and cloxacillin had salivary excretion with correlation coefficients of 0.59-0.99 between saliva and plasma concentrations. On the other hand, montelukast, lornoxicam, diacerhein, losartan and tamsulosin showed no salivary excretion. Estimated Peff ranged 0.16-44.16 × 10(-4) cm/s, while reported fraction unbound to plasma proteins (fu) ranged 0.01-0.99 for the drugs under investigation. Saliva/plasma concentrations ratios ranged 0.11-13.4, in agreement with drug protein binding and permeability. A Salivary Excretion Classification System (SECS) was suggested based on drug high (H)/low (L) permeability and high (H)/low (L) fraction unbound to plasma proteins, which classifies drugs into 4 classes. Drugs that fall into class I (H/H), II (L/H) or III (H/L) are subjected to salivary excretion, while those falling into class IV (L/L) are not. Additional data from literature was also analyzed, and all results were in agreement with the suggested SECS. Moreover, a polynomial relationship with correlation coefficient of 0.99 is obtained between S* and C*, where S* and C* are saliva and concentration dimensionless numbers respectively. The proposed Salivary Excretion Classification System (SECS) can be used as a guide for drug salivary excretion. Future work is planned to test these initial findings, and demonstrate SECS robustness across a range of carefully selected (based on physicochemical properties) drugs that fall into classes I, II or III.


Subject(s)
Saliva/metabolism , Acetates/blood , Acetates/pharmacokinetics , Anthraquinones/blood , Anthraquinones/pharmacokinetics , Azithromycin/blood , Azithromycin/pharmacokinetics , Benzhydryl Compounds/blood , Benzhydryl Compounds/pharmacokinetics , Cinacalcet , Cloxacillin/blood , Cloxacillin/pharmacokinetics , Cresols/blood , Cresols/pharmacokinetics , Cyclopropanes , Female , Fluorobenzenes/pharmacokinetics , Fluorobenzenes/pharmacology , Humans , Hydrochlorothiazide/blood , Hydrochlorothiazide/pharmacokinetics , Losartan/blood , Losartan/pharmacokinetics , Male , Metformin/blood , Metformin/pharmacokinetics , Naphthalenes/blood , Naphthalenes/pharmacokinetics , Phenylpropanolamine/blood , Phenylpropanolamine/pharmacokinetics , Piroxicam/analogs & derivatives , Piroxicam/blood , Piroxicam/pharmacokinetics , Pyrazines/blood , Pyrazines/pharmacokinetics , Pyrimidines/pharmacokinetics , Pyrimidines/pharmacology , Quinolines/blood , Quinolines/pharmacokinetics , Rosuvastatin Calcium , Sitagliptin Phosphate , Sulfides , Sulfonamides/blood , Sulfonamides/pharmacokinetics , Sulfonamides/pharmacology , Tamsulosin , Tolterodine Tartrate , Triazoles/blood , Triazoles/pharmacokinetics
4.
J Chemother ; 23(5): 277-81, 2011 Oct.
Article in English | MEDLINE | ID: mdl-22005059

ABSTRACT

The aim of the present retrospective observational clinical study was to assess the interindividual pharmacokinetic variability of plasma concentrations of amoxicillin or cloxacillin administered in high doses intravenously in critically ill patients, related to renal function or administration method.Four hundred and two plasma concentrations were measured at steady-state with a high performance liquid chromatography technique in 162 patients treated with 100 - 300 mg/kg/day of intravenous amoxicillin or cloxacillin.For both drugs and administration methods, plasma concentrations were significantly higher for patients with creatinine clearance below 60 ml/min, even though doses were adapted for renal impairment. the correlations calculated between plasma concentrations and creatinine level, creatinine clearance or doses were all low. There were fewer outlying drug concentrations in patients receiving continuous rather than intermittent regimens.Our results are in favor of adapting dosages of these beta-lactam antibiotics based on plasma concentrations, especially in cases of renal impairment.


Subject(s)
Amoxicillin/pharmacokinetics , Anti-Bacterial Agents/pharmacokinetics , Bacterial Infections/drug therapy , Cloxacillin/pharmacokinetics , Renal Insufficiency/complications , Adult , Aged , Aged, 80 and over , Amoxicillin/administration & dosage , Amoxicillin/blood , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/blood , Bacterial Infections/complications , Bacterial Infections/microbiology , Bacterial Infections/physiopathology , Cloxacillin/administration & dosage , Cloxacillin/blood , Creatinine/blood , Creatinine/metabolism , Drug Administration Schedule , Endocarditis, Bacterial/complications , Endocarditis, Bacterial/drug therapy , Endocarditis, Bacterial/microbiology , Endocarditis, Bacterial/physiopathology , Female , Humans , Infusions, Intravenous , Intensive Care Units , Male , Medical Records , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Middle Aged , Reproducibility of Results , Retrospective Studies , Severity of Illness Index , Streptococcal Infections/complications , Streptococcal Infections/drug therapy , Streptococcal Infections/microbiology , Streptococcal Infections/physiopathology
5.
Clin Ther ; 31(5): 999-1006, 2009 May.
Article in English | MEDLINE | ID: mdl-19539100

ABSTRACT

BACKGROUND: Plasma concentrations of cloxacillin have been found to vary as much as 20-fold among individuals receiving the same oral dose. There is evidence that cloxacillin may be a substrate for P-glycoprotein, suggesting that polymorphisms in the ABCB1 gene may be a contributing factor to the observed variability in plasma cloxacillin concentrations. OBJECTIVE: This study investigated the effect of ABCB1 polymorphisms on the pharmacokinetic profile of cloxacillin in healthy subjects. METHODS: A single oral dose of cloxacillin 500 mg was administered to healthy Chinese male subjects under fasting conditions. Serial blood and urine samples were collected for up to 6 hours after administration. A high-performance liquid chromatography method was used to determine plasma cloxacillin pharmacokinetics and urinary excretion. A polymerase chain reaction technique was used for genotyping of 3 single nucleotide polymorphisms (SNPs) of the ABCB1 gene: exon 12 C1236T, exon 21 G2677T/A, and exon 26 C3435T. Cloxacillin pharmacokinetic parameters and urinary excretion were then compared according to genotype and haplotype groups. RESULTS: The study included 18 healthy Chinese male subjects who ranged in age from 21 to 26 years, had a mean weight ranging from 55.6 to 70.6 kg, and had normal renal function at baseline (mean [SD] serum creatinine, 93.4 [11.0] micromol/L). Plasma concentrations of cloxacillin were generally lower in the group carrying the 1236CC genotype (n = 3) compared with those carrying the 1236CT genotype (n = 9) or the 1236TT genotype (n = 6). Compared with the other groups, carriers of the 1236CC genotype had a significantly lower mean Cmax (-53%; P = 0.013) and AUC(0-infinity) (-40%; P = 0.044), and a significantly higher mean apparent oral clearance (35%; P = 0.013). They also had significantly lower urinary excretion of cloxacillin over 6 hours (-52%; P = 0.027). There were no significant differences in cloxacillin t(1/2) or renal clearance between the 3 C1236T genotypes, nor was the G2677T or C3435T SNP associated with any significant changes in the cloxacillin pharmacokinetic profile. Among subjects with 1 of the 3 major haplotype pairs, those carrying the CGC/CGC pair had a significantly lower C(max) (P = 0.017), AUC (P = 0.032), and urinary excretion of cloxacillin (P = 0.026) compared with those carrying the CGC/TGC and TTT/TTT pairs. CONCLUSIONS: In this small population of healthy Chinese men, the C1236T variant of ABCB1 appeared to be an important contributor to interindi-vidual differences in plasma cloxacillin exposure, most likely through an effect on oral absorption rather than on disposition. Studies of multiple doses in larger sample sizes are needed to confirm these findings.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , Anti-Bacterial Agents/pharmacokinetics , Asian People/genetics , Cloxacillin/pharmacokinetics , Genes, MDR/genetics , Polymorphism, Single Nucleotide/genetics , ATP Binding Cassette Transporter, Subfamily B , ATP Binding Cassette Transporter, Subfamily B, Member 1/blood , ATP Binding Cassette Transporter, Subfamily B, Member 1/urine , Administration, Oral , Adult , Anti-Bacterial Agents/blood , Anti-Bacterial Agents/urine , Chromatography, High Pressure Liquid , Cloxacillin/blood , Cloxacillin/urine , Humans , Male , Polymerase Chain Reaction , Reference Values , Young Adult
6.
J Chromatogr B Analyt Technol Biomed Life Sci ; 854(1-2): 85-90, 2007 Jul 01.
Article in English | MEDLINE | ID: mdl-17462966

ABSTRACT

A weak ion exchange monolithic column prepared by modifying the GMA-MAA-EDMA (glycidyl methacrylate-methacrylic acid-ethylene glycol dimethacrylate) monoliths with ethylenediamine was applied to remove matrix compounds in biological fluid. Using this monolithic column, on-line clean-up and screening of oxacillin and cloxacillin in human urine and plasma samples had been investigated. Chromatography was performed by reversed-phase HPLC on a C(18) column with ultraviolet detection at 225 nm. Results showed that the ion exchange monolithic column could be used for deproteinization and retaining oxacillin and cloxacillin in human urine and plasma, which provided a simple and fast method for assaying drugs in human urine and plasma.


Subject(s)
Anti-Bacterial Agents/analysis , Chromatography, Ion Exchange/instrumentation , Cloxacillin/analysis , Oxacillin/analysis , Anti-Bacterial Agents/blood , Anti-Bacterial Agents/urine , Calibration , Cloxacillin/blood , Cloxacillin/urine , Humans , Hydrogen-Ion Concentration , Oxacillin/blood , Oxacillin/urine , Reproducibility of Results
7.
Antimicrob Agents Chemother ; 50(12): 4011-7, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17015630

ABSTRACT

Antimicrobial efficacy in orthopedic device infections is diminished because of bacterial biofilms which express tolerance to antibiotics. Recently, the use of high doses of levofloxacin with rifampin has been recommended for staphylococcal infections. In the present study, we evaluated the efficacy of levofloxacin at doses of 50 mg/kg/day and 100 mg/kg/day (mimicking the usual and high human doses of 500 mg/day and 750 to 1,000 mg/day, respectively) and compared it to that of to linezolid, cloxacillin, vancomycin, and rifampin in a rat tissue cage model of experimental foreign-body infection by Staphylococcus aureus. The antimicrobial efficacy in vitro (by MIC, minimum bactericidal concentration, and kill curves) for logarithmic- and stationary-phase bacteria was compared with the in vivo efficacy. In vitro bactericidal activity at clinically relevant concentrations was reached by all drugs except rifampin and linezolid in the log-phase studies but only by levofloxacin in the stationary-phase studies. The bacterial count decreases from in vivo tissue cage fluids (means) for levofloxacin at 50 and 100 mg/kg/day, rifampin, cloxacillin, vancomycin, linezolid, and controls, respectively, were: -1.24, -2.26, -2.1, -1.56, -1.47, -1.15, and 0.33 (all groups versus controls, P < 0.05). Levofloxacin at 100 mg/kg/day (area under the concentration-time curve/MIC ratio, 234) was the most active therapy (P = 0.03 versus linezolid). Overall, in vivo efficacy was better predicted by stationary-phase studies, in which it reached a high correlation coefficient even if the rifampin group was excluded (r = 0.96; P < 0.05). Our results, including in vitro studies with nongrowing bacteria, pharmacodynamic parameters, and antimicrobial efficacy in experimental infection, provide good evidence to support the use of levofloxacin at high doses (750 to 1,000 mg/day), as recently recommended for treating patients with orthopedic prosthesis infections.


Subject(s)
Anti-Bacterial Agents/pharmacology , Foreign-Body Reaction , Levofloxacin , Methicillin/pharmacology , Ofloxacin/pharmacology , Staphylococcus aureus/drug effects , Acetamides/blood , Acetamides/pharmacokinetics , Acetamides/pharmacology , Acetamides/therapeutic use , Animals , Anti-Bacterial Agents/blood , Anti-Bacterial Agents/pharmacokinetics , Anti-Bacterial Agents/therapeutic use , Anti-Infective Agents/blood , Anti-Infective Agents/pharmacokinetics , Anti-Infective Agents/pharmacology , Anti-Infective Agents/therapeutic use , Cloxacillin/blood , Cloxacillin/pharmacokinetics , Cloxacillin/pharmacology , Cloxacillin/therapeutic use , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Foreign-Body Reaction/drug therapy , Foreign-Body Reaction/prevention & control , Humans , Linezolid , Male , Methicillin/blood , Methicillin/pharmacokinetics , Microbial Sensitivity Tests , Ofloxacin/blood , Ofloxacin/pharmacokinetics , Ofloxacin/therapeutic use , Oxazolidinones/blood , Oxazolidinones/pharmacokinetics , Oxazolidinones/pharmacology , Oxazolidinones/therapeutic use , Rats , Rats, Wistar , Rifampin/blood , Rifampin/pharmacokinetics , Rifampin/pharmacology , Rifampin/therapeutic use , Staphylococcal Infections/drug therapy , Staphylococcal Infections/prevention & control , Vancomycin/blood , Vancomycin/pharmacokinetics , Vancomycin/pharmacology , Vancomycin/therapeutic use
8.
J Pharm Biomed Anal ; 36(5): 961-8, 2005 Jan 04.
Article in English | MEDLINE | ID: mdl-15620520

ABSTRACT

In the framework of a preliminary investigation on the plasma profile of cloxacillin after oral administration, a simple and rapid LC method was developed for the direct determination of this compound in human plasma. The on-line sample clean-up was carried out using a weak anion exchanger (diethylaminoethyl groups) as restricted access material (RAM). The effects of the washing liquid pH, the ionic strength and the addition of organic modifier to the washing liquid were studied in order to obtain an efficient sample clean-up and a high recovery of cloxacillin. The separation was achieved on octadecylsilica stationary phase using a mobile phase consisting in a mixture of phosphate buffer (pH 4.0; 25 mM) and acetonitrile (72:28, v/v). The UV detection was performed at 215 nm. The most appropriate regression model of the response function as well as the limit of quantitation (LOQ) were first selected during the pre-validation step. These criteria were then assessed during the formal validation step. The LOQ was 50 ng/ml. The method was also validated with respect to analyte recovery, precision, trueness, accuracy and linearity. Finally, it was successfully applied for the analysis of the first plasma samples obtained from patients having taken an oral dose of 500 mg cloxacillin.


Subject(s)
Anion Exchange Resins/analysis , Cloxacillin/blood , Chromatography, Liquid/methods , Humans
9.
J Antimicrob Chemother ; 43(4): 593-6, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10350394

ABSTRACT

Fusidic acid and cloxacillin were studied in patients who underwent joint aspiration for noninfectious disorders. Nine patients were given oral 500 mg fusidic acid tid for 72 h, the last dose being given 4, 8 or 12 h before the joint aspiration. Cloxacillin was administered in a single 2 g iv dose to 9 patients, 0.5, 4 or 8 h before the aspiration. Bactericidal activity was determined against five isolates each of methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Satisfactory activity (> or = 1:3) was detected in the serum in patients who received fusidic acid, while in the synovial fluids titres reflected borderline effectiveness (c. 1:2). Despite drug concentrations and excellent MICs, fusidic acid demonstrated markedly lower inhibitory and bactericidal activity against S. aureus than did cloxacillin.


Subject(s)
Anti-Bacterial Agents/analysis , Cloxacillin/analysis , Fusidic Acid/analysis , Staphylococcus aureus/drug effects , Synovial Fluid/chemistry , Adult , Aged , Aged, 80 and over , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/blood , Anti-Bacterial Agents/pharmacology , Arthritis, Infectious/drug therapy , Biopsy, Needle , Cloxacillin/administration & dosage , Cloxacillin/blood , Cloxacillin/pharmacology , Female , Fusidic Acid/administration & dosage , Fusidic Acid/blood , Fusidic Acid/pharmacology , Humans , Knee Joint , Male , Methicillin Resistance , Middle Aged , Penicillins/administration & dosage , Penicillins/analysis , Penicillins/blood , Penicillins/pharmacology
10.
Diagn Microbiol Infect Dis ; 33(1): 39-42, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9990474

ABSTRACT

Cefepime (1 g), ceftazidime (1 g), and cloxacillin (2 g) were administered intravenously to 10 volunteers each. After infusion of a single dose over 30 min, blood samples were obtained at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, and 12 h (for ceftazidime at 0.5 and 4 h) after dosing. Drug levels were determined by the bioassay method. Serum bactericidal activity against five clinical isolates of cloxacillin-susceptible Staphylococcus aureus were determined by the microdilution method according to the National Committee for Clinical Laboratory Standards guidelines. The mean peak serum level was 76.88 +/- 24.71 mg/L for cefepime, 42.8 +/- 15.98 mL/L for ceftazidime, and 92.81 +/- 24.7 mg/L for cloxacillin. Concentrations of cefepime were detected during the whole testing period (mean trough level, 1.43 +/- 0.9 mg/L at 12 h), whereas concentrations of cloxacillin were measurable up to 5 h after administration (mean trough level, 0.90 +/- 0.97 mg/L). The mean peak reciprocal bactericidal titers were 29.41 for cefepime, 5.6 for ceftazidime, and 377 for cloxacillin. Effective bactericidal titers were detected as long as 5 h for cefepime (approximately 40% of the dosing interval) and 3 h for cloxacillin (at least 50% of the dosing interval). For ceftazidime, serum bactericidal activity was markedly lower compared with that of cefepime. Although cefepime has demonstrated an improved antistaphylococcal bactericidal activity compared with ceftazidime, it was somewhat lower than that of cloxacillin.


Subject(s)
Anti-Bacterial Agents/pharmacology , Ceftazidime/pharmacology , Cephalosporins/pharmacology , Cloxacillin/pharmacology , Staphylococcus aureus/drug effects , Adult , Anti-Bacterial Agents/blood , Cefepime , Ceftazidime/blood , Cephalosporins/blood , Cloxacillin/blood , Female , Humans , Male , Middle Aged
11.
J Chromatogr B Biomed Sci Appl ; 698(1-2): 155-60, 1997 Sep 26.
Article in English | MEDLINE | ID: mdl-9367203

ABSTRACT

A rapid and sensitive high-performance liquid chromatographic method is described for the determination of cloxacillin residues in milk and serum. Only a clean-up step after deproteinization is necessary before the analysis. The chromatographic system involves the use of a C18 column and ultraviolet absorbance detection at 225 nm. The mobile phase was acetonitrile-0.02 M KH2PO4 (21:79) at pH 5. Recoveries for cloxacillin were 83.5 and 75.7% in serum and milk, respectively. Detection limits (10 ng/ml in milk and 50 ng/ml in serum) were below the stipulated European Union maximum residue limits for cloxacillin. Thus, the described method showed the same accuracy, precision and sensitivity as the microbiological assays but without interferences caused by other drugs commonly used in therapy. Analysis of different blood and milk samples obtained at different times from dairy cows treated with an intramammary dose of cloxacillin benzatine showed undetectable cloxacillin levels both in milk and blood samples.


Subject(s)
Chromatography, High Pressure Liquid/methods , Cloxacillin/analysis , Milk/chemistry , Penicillins/analysis , Animals , Cattle , Cloxacillin/blood , Penicillins/blood , Reference Standards , Reproducibility of Results , Spectrophotometry, Ultraviolet
12.
Pharmacol Toxicol ; 81(1): 26-30, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9258981

ABSTRACT

We studied the influence of diclofenac on the pharmacokinetics of cloxacillin in healthy volunteers, 60 years or older, as well as the possible effect of cloxacillin and diclofenac on urinary protein excretion. In a randomized, double-blind, cross-over study 15 subjects were given 1 g cloxacillin, and placebo or 75 mg diclofenac, as single intravenous doses. Plasma concentrations of cloxacillin were followed over 10.5 hr, and urine excretion of cloxacillin over 24 hr. The effect of the drugs on urinary excretion of protein indicators of glomerular (albumin, IgG) and tubular (protein HC) function was also studied. Total plasma clearance of cloxacillin was with placebo 219 +/- 51 (mean +/- S.D.), and with diclofenac 212 +/- 39 ml/min./1.73 m2 (ns); renal clearance was 97 +/- 21 and 96 +/- 24 ml/min./1.73 m2, respectively (ns). The terminal t1/2 of cloxacillin was 1.03 +/- 0.42 hr with placebo, and 1.12 +/- 0.37 with diclofenac (ns). The mean ratio of AUC0-infinity's (cloxacillin plus diclofenac/cloxacillin plus placebo) was 1.03 (90% CI: 0.99, 1.08). Urinary excretion of the proteins was low and was not increased by cloxacillin or diclofenac. In healthy volunteers, 60 years or older, diclofenac does not alter cloxacillin pharmacokinetics, and neither cloxacillin nor diclofenac in single intravenous doses cause renal dysfunction.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Cloxacillin/pharmacokinetics , Diclofenac/pharmacology , Penicillins/pharmacokinetics , Aged , Aged, 80 and over , Albuminuria , Cloxacillin/blood , Creatinine/urine , Cross-Over Studies , Double-Blind Method , Female , Humans , Kidney/drug effects , Male , Middle Aged , Penicillins/blood , Proteins/drug effects , Proteins/metabolism , Time Factors
13.
Arzneimittelforschung ; 44(5): 671-3, 1994 May.
Article in English | MEDLINE | ID: mdl-8024646

ABSTRACT

Using dynamic and equilibrium dialysis methods, it has been demonstrated that ascorbic acid (CAS 50-81-7) inhibits the binding of cloxacillin sodium (CAS 7081-44-9) to bovine serum albumin (BSA) in vitro. Normally, ascorbic acid has a lower number of binding sites and a much lower binding constant for BSA than cloxacillin sodium. There is an indication that ascorbic acid inhibits the binding of cloxacillin to BSA through a noncompetitive mechanism. The probable interactions leading to the non-competitive inhibition were suggested.


Subject(s)
Ascorbic Acid/pharmacology , Cloxacillin/blood , Serum Albumin, Bovine/metabolism , Animals , Cattle , Depression, Chemical , Dialysis , Protein Binding/drug effects
14.
Br J Clin Pharmacol ; 36(1): 57-60, 1993 Jul.
Article in English | MEDLINE | ID: mdl-8373712

ABSTRACT

1. Eleven patients undergoing lumbar discectomy received cloxacillin by continuous i.v. infusion, starting before the operation. During the operation several blood samples and one CSF sample were taken. 2. Mean rate constants describing the passive transfer of drug from plasma to CSF (kp) and the largely active transfer in the opposite direction (kCSF) were estimated. 3. In some subjects the CSF albumin quotient, defined as the ratio between the albumin concentration in CSF and in plasma times 1000, was slightly elevated (up to 23) which caused a significant increase in the value of kp. 4. The estimate of mean kp for healthy individuals was 0.065 h-1, which corresponds to a half-life of 10 h. The estimate of mean kCSF was 2.10 h-1. This predicts a steady-state CSF drug concentration which is 3% of the unbound plasma drug concentration. 5. There was a significant lag between the time courses of plasma and CSF drug concentrations, presumably reflecting the time for drug to move from the choroid plexus to the lumbar sampling site. 6. Four other patients received cloxacillin for prophylactic or therapeutic reasons by continuous i.v. infusion. In three of those patients the albumin quotient was normal or slightly elevated and the steady-state CCSF/Cu ratio was similar to the predicted normal value. 7. These findings indicate that eradicating staphylococci from CSF in cases of meningitis with a low degree of inflammation may be difficult.


Subject(s)
Cloxacillin/cerebrospinal fluid , Meningitis/cerebrospinal fluid , Cloxacillin/blood , Cloxacillin/pharmacokinetics , Half-Life , Humans , Models, Biological , Protein Binding , Serum Albumin/metabolism
15.
Br J Clin Pharmacol ; 34(3): 275-7, 1992 Sep.
Article in English | MEDLINE | ID: mdl-1389954

ABSTRACT

After a 30 min i.v. infusion of 1 g cloxacillin, the concentrations of this antibiotic were measured in plasma and synovial tissue samples from 11 patients undergoing total hip replacement. Assuming passive distribution between plasma and tissue the rate constants of distribution were estimated. The mean half-life of distribution was 22 min. The concentration of free drug in synovial tissue was estimated to be 77% of the total tissue concentration. The maximum tissue drug concentration after an i.v. bolus dose is predicted to occur at about 37 min.


Subject(s)
Cloxacillin/pharmacokinetics , Synovial Membrane/metabolism , Aged , Aged, 80 and over , Cloxacillin/blood , Diffusion , Female , Humans , Male , Middle Aged , Tissue Distribution
16.
J Infect Dis ; 163(3): 640-3, 1991 Mar.
Article in English | MEDLINE | ID: mdl-1995736

ABSTRACT

The role of Staphylococcus aureus tolerance was investigated in endocarditis in rats. The efficacies of cloxacillin, gentamicin, and a combination of the two were compared for animals infected with a tolerant strain, its kill-sensitive variant, or a nonisogenic nontolerant strain of S. aureus. Cloxacillin was significantly less effective for treating the tolerant than for the nontolerant strains. The addition of gentamicin to cloxacillin reduced bacterial numbers in endocardial vegetations for the tolerant strain comparable to the reduction by cloxacillin alone for the nontolerant strains, but had no additional effect for the nontolerant strains. Isolates from animals infected with the tolerant or nontolerant strains during antibiotic treatment remained tolerant or nontolerant. These results show that the in vitro phenomenon of tolerance is relevant in vivo.


Subject(s)
Cloxacillin/therapeutic use , Endocarditis, Bacterial/drug therapy , Staphylococcal Infections/drug therapy , Staphylococcus aureus/drug effects , Animals , Cloxacillin/blood , Disease Models, Animal , Endocarditis, Bacterial/blood , Female , Microbial Sensitivity Tests , Penicillin Resistance , Random Allocation , Rats , Rats, Inbred Strains , Staphylococcal Infections/blood
17.
Scand J Infect Dis ; 23(2): 233-8, 1991.
Article in English | MEDLINE | ID: mdl-1853173

ABSTRACT

Concentrations of cloxacillin in plasma and deep thoracic muscle tissue were measured in 10 patients who underwent elective coronary bypass surgery or valve replacement. One g of cloxacillin was administered after the induction of anaesthesia and 1 g cloxacillin was added to the oxygenator pump priming fluid before the start of the procedure. Blood and tissue samples were obtained before, during and after cardiopulmonary bypass. The relation between unbound plasma concentrations and total tissue contents of the drug was calculated. It was shown that measurement of the free plasma concentration may provide fairly reliable information on the free concentrations of cloxacillin in the tissues, and that determination of tissue contents may therefore not be necessary. Due to the administration of the second dose of cloxacillin at the start of cardiopulmonary bypass free tissue contents were just adequate in most patients. However, to obtain adequate tissue concentrations after bypass it is recommended that a third dose of the antibiotic be administered before the end of the operation.


Subject(s)
Cloxacillin/analysis , Coronary Artery Bypass , Muscles/chemistry , Adult , Aged , Cloxacillin/administration & dosage , Cloxacillin/blood , Female , Humans , Male , Middle Aged , Time Factors
18.
Antimicrob Agents Chemother ; 34(12): 2348-53, 1990 Dec.
Article in English | MEDLINE | ID: mdl-1965105

ABSTRACT

The in vivo efficacy of daptomycin, a new cell wall-active anti-gram-positive-bacterial agent, was compared to those of cloxacillin and vancomycin in a rat model of Staphylococcus aureus endocarditis. Both methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) strains were used. When therapy was initiated early (8 h) after infection, at the time when valvular bacterial counts were relatively low (approximately 10(6) CFU/g of vegetation), 3 days of therapy was found to be effective against the MSSA strains whatever the antibiotic regimen. In contrast, when the onset of therapy was delayed up to 15 h after infection, so that higher bacterial counts could develop on the valves (approximately 10(9) CFU/g of vegetation), a longer period of treatment (6 days) was required to cure infection. Under these conditions after 3 days of therapy, daptomycin was more effective than cloxacillin and vancomycin against the MSSA strains. Similarly, daptomycin showed a greater activity than vancomycin against the MRSA strain after 3 days of treatment, but after 6 days both antibiotics were equally effective. Decreasing doses of daptomycin showed decreasing activity: 10 mg/kg of body weight every 12 h (q12h) was better than 5 mg/kg q12h, whereas 5 mg/kg q24h (providing drug levels in blood detectable only during the first 12 h) failed to cure infection. In vitro, daptomycin was highly bactericidal at high concentrations (25 and 60 micrograms/ml, corresponding to peak levels in serum after doses of 5 and 10 mg/kg, respectively) and bacteriostatic at lower concentrations (0.5 to 2.5 micrograms/ml, corresponding to trough levels in serum). In conclusion, against low-bacterial-count S. aureus endocarditis, daptomycin showed an efficacy similar to those of vancomycin and cloxacillin. Against high-bacterial-count S. aureus endocarditis, daptomycin showed a higher bactericidal activity than cloxacillin (against the MSSA strains) and vancomycin (against both the MSSA and MRSA strains).


Subject(s)
Cloxacillin/therapeutic use , Endocarditis, Bacterial/drug therapy , Staphylococcal Infections/drug therapy , Vancomycin/therapeutic use , Animals , Cloxacillin/blood , Daptomycin , Endocarditis, Bacterial/microbiology , Female , Microbial Sensitivity Tests , Peptides/blood , Peptides/therapeutic use , Rats , Rats, Inbred Strains , Staphylococcal Infections/microbiology , Staphylococcus aureus/drug effects , Vancomycin/blood
19.
Antimicrob Agents Chemother ; 34(6): 1150-3, 1990 Jun.
Article in English | MEDLINE | ID: mdl-2393274

ABSTRACT

To determine the magnitude of cloxacillin loss during surgical procedures involving significant blood loss and high fluid replacement, we compared the pharmacokinetics of cloxacillin in children during craniomaxillofacial surgery with the disposition of the drug in healthy young adult volunteers with intact circulation. Blood loss during craniofacial operations may exceed blood volume, in some cases by as much as three times. Hemodynamic replacement with electrolyte solutions and blood products, which do not contain the drug, further dilute cloxacillin concentrations. In the patients that we studied, mean drug loss was estimated at 71%. Cloxacillin concentrations in serum fell below the lower range of the MIC for Staphylococcus aureus during significant portions of the surgical procedures. Thus, the traditional dosing of cloxacillin during prolonged operations with massive blood loss is inadequate. A more frequent dosing interval or priming of all replacement fluids with the drug may be required to maintain therapeutic levels. Our findings suggest that massive blood loss is likely to have a dramatic effect on the level of any drug with a small distribution volume. If such a drug is essential to the patient's well-being (e.g., antibiotics, antiarrhythmics, and anticonvulsants), it must be replaced promptly.


Subject(s)
Cloxacillin/pharmacokinetics , Hemorrhage/metabolism , Intraoperative Complications/metabolism , Adolescent , Adult , Anesthesia , Child , Child, Preschool , Cloxacillin/administration & dosage , Cloxacillin/blood , Female , Humans , Infant , Infusions, Intravenous , Injections, Intravenous , Male , Reference Values , Serum Bactericidal Test
20.
Am J Vet Res ; 51(3): 381-5, 1990 Mar.
Article in English | MEDLINE | ID: mdl-2316914

ABSTRACT

Disposition kinetics of cloxacillin were examined in calves after topical administration of benzathine cloxacillin and single IV administration of sodium cloxacillin, and the susceptibility of 17 field isolates of Moraxella bovis was measured. For the IV pharmacokinetic phase, sodium cloxacillin was administered at dosage of 10 mg/kg of body weight to male Holstein calves (n = 6, weighing 146 to 170 kg), and serum concentration of cloxacillin was measured thereafter for 10 hours. For the ocular pharmacokinetic phase, 6 calves were given either of 4 benzathine cloxacillin topical formulations consisting of 50-, 125-, 250-, or 375-mg doses. Treatment was repeated every 10 days until all 4 benzathine cloxacillin dosages were tested in the same 6 calves. Blood and tears were collected for 72 hours after each benzathine cloxacillin formulation was administered, and the concentration of cloxacillin in each specimen was measured, using a bioassay. The minimal inhibitory concentration of cloxacillin for 17 field isolates of M bovis was determined by use of an agar pour-plate dilution assay. After single IV administration of sodium cloxacillin, its half-life, body clearance, and volume of distribution were 19.5 +/- 12.8 minutes, 18.3 +/- 2.2 ml/min.kg, and 496 +/- 290 ml/kg, respectively. After topical administration of benzathine cloxacillin, cloxacillin concentration in lacrimal fluid peaked between 30 and 45 minutes and ranged between 963 micrograms/ml and 3,256 micrograms/ml for the 125- and 375-mg doses, respectively. There was no detectable cloxacillin activity in the lacrimal fluid of any calf by 36 hours after topical administration of benzathine cloxacillin, and cloxacillin was not detected in the serum at any time.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Cattle , Cloxacillin/pharmacokinetics , Moraxella/drug effects , Tears/analysis , Administration, Topical , Animals , Cloxacillin/administration & dosage , Cloxacillin/analogs & derivatives , Cloxacillin/blood , Dose-Response Relationship, Drug , Half-Life , Injections, Intravenous/veterinary , Male , Metabolic Clearance Rate , Moraxella/isolation & purification , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...